Topics

Companies Related to "Type ineffectively activates neonatal dendritic cells limiting respiratory" [Most Relevant Company Matches] RSS

14:47 EST 25th January 2020 | BioPortfolio

Here are the most relevant search results for "Type ineffectively activates neonatal dendritic cells limiting respiratory" found in our extensive corporate database of over 50,000 company records.

Showing "Type ineffectively activates neonatal dendritic cells limiting respiratory" Companies 1–25 of 1,500+

Relevant

BioTime, Inc. and Asterias Biotherapeutics, Inc.

Asterias Biotherapeutics, Inc. is a leading biotechnology company in the emerging field of regenerative medicine. The company’s proprietary, industry leading platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias is focused on developing therapies to treat conditions in several medical areas where ther...


Betalin Therapeutics Ltd.

Pancreatic islet transplantation is currently performed in certain patients with Type 1 diabetes whose blood glucose levels are difficult to control. Pancreatic islet transplantation is a procedure in which islets, containing beta cells, from the pancreas of a deceased organ donor are purified, processed, and transferred into another person. Transplant ...

VivoScript, Inc.

Based in Orange County, California, VivoScript is an emerging biotech company established to commercialize a disruptive innovation in regenerative medicine. The new technology platform is named In Vivo Cell Reprogramming, or IVR. Using a combination of protein drugs, we can convert or reprogram one type of cells (substrate cells) to another type of cells (...


Dendritic NanoTechnologies Inc

Dendritic NanoTechnologies Inc. (DNT) is the world’s leading developer and provider of advanced dendritic polymers. DNT has breakthrough technology that provides the vehicle — the targeting and delivery mechanisms — for a vast array of diagnostics and therapeutics currently in development in the biotechnology and pharmaceutical industries.DNT is a U.S. company incorporated in 2003 and locate...

3H Biomedical

3H Biomedical is an innovative Swedish life-science company that develops, manufactures and markets primary cells, cellular products and cell-based assays for cell research, drug discovery and tissue engineering research. We offer a variety of 'ready-to-use' high-value primary human adult stem cells, dendritic cells, lymphocytes, NK cells, monocytes and EPCs. We serve the research community, the ...

Ximerex, Inc

Ximerex, Inc. is developing platform technologies for the treatment of organ failure.We have proprietary and patented technology for growing foreign cells, including human cells, within fetal pigs. Later, xenografts from humanized pigs are accepted without substantially limiting the patient's ability to fight infections.Ximerex will provide the humanized pig organs and cells for transplantation.

NICU Solutions, Inc

Linda is the Founder and President of NICU Solutions, Inc., and has been involved in neonatal nursing since 1983. She has worked in a variety of roles, including staff nurse, charge nurse, transport nurse, preceptor, clinical educator, neonatal nurse practitioner, and case manager. She has published widely in national journals including Neonatal Network, JOGNN, and The American Journal of Perinato...

IRX Therapeutics, Inc.

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine co...

Specific Technologies

Specific Technologies has developed in vitro systems for rapid identification of cells, and is applying this fundamental new platform to the detection and characterization of microorganisms causing blood infection. The company is also exploring applications for antibiotic drug discovery and the identification of tumor cells by type and mutation variant. Th...

GenSpera, Inc.

GenSpera, Inc. is a development stage oncology company focused on therapeutics that deliver a potent, unique and patented drug directly to tumors. GenSpera’s technology platform combines a potent cytotoxin (12ADT) with a pro-drug delivery system that activates the drug only within the tumor. Unlike standard cancer drugs, plant-derived 12ADT kills cell...

Celldex therapeutics

Celldex is a biotechnology company focused on the discovery, development and commercialization of novel immunotherapeutics including human monoclonal antibodies for the treatment of cancer, infectious diseases, and immune system disorders. We are advancing a pipeline of clinical and pre-clinical product candidates.Our proprietary core technology utilizes human monoclonal antibodies to directly tar...

Argos Therapeutics

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.a...

Tau Therapeutics LLC

Tau Therapeutics is a clinical stage company developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel – a novel mechanism of action for cancer. The company’s approach, called Interlaced Therapy™, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type ...

DCPrime

DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. DCOne-based dendritic cell vaccines, in some indications loaded with cancer antigens for targeted treatment, are used as standardized, therapeutic products. The platform combines the power of den...

Diamyd Medical AB

Founded in 1996, Diamyd Medical AB (OMXS: DIAM B) (OTCBB: DMYDY), is an emerging and global biotechnology company based in Stockholm, Sweden and Pittsburgh, PA, USA. Diamyd Medical is focused on developing treatments for diabetes, both Type 1 and Type 2, via GAD protein therapy. Its lead drug candidate, Diamyd™, is designed to reduce the need of insulin injections and prevent the destruction of ...

BioVex

BioVex is a three year old private biotech company that is developing a new class of potent vaccines principally to treat and prevent cancer. The Company is headquartered in Oxford, UK. The Company has three technology platforms based on the manipulation of the herpes simplex type one virus. The Company has two vaccine platforms; OncoVEX and ImmunoVEX and a functional genomics platform for gene de...

Respiratory Therapeutics Group

RTG is a global manufacturer of Respiratory Devices, with an extensive brand portfolio of respiratory disposable devices, products and service solutions designed by Respiratory Therapists for a diverse range of therapies. RTG Products are distributed in Acute, Sub Acute, Skilled Nursing, Home and Hospice Settings, through our increasing network of d...

Allegro Diagnostics Corp.

Allegro Diagnostics’ molecular testing platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer and diseases of the airway. The “field of injury” principle on which the platform is based refers to the detectable molecular changes that occur throughout the respiratory tract in ...

Tetra Link International

Antibodies for ImmunohistochemistryOX-2 Antibodies (human, mouse, rat)rProtein L and rProtein LAanti-human, anti-mouse, and anti-rat OX-2 antibodies which play a role in immunomodulation. Several other immunomodulating antibodies against dendritic cells.

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...

Northwest Biotherapeutics

Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against ...

Lava Therapeutics

Lava Therapeutics’ proprietary platform is focused on developing next generation γδ T cell engaging bispecific antibodies to treat cancer. Our first-in-class immuno-oncology approach activates Vγ9Vδ2 T cells upon binding to membrane-expressed tumor targets. Lava’s vision is to develop therapeutics for the curative treatment of cancer. Founde...

National Board for Respiratory Care

With the mission of promoting excellence in respiratory care by awarding credentials based on high competency standards, The National Board for Respiratory Care seeks to protect and enhance patient lives. Nearly 30,000 candidates test for the NBRC credentials each year to demonstrate how excellence defines them across seven specific areas of respiratory care. All 49 states regulating the professi...

Embria Health Sciences

Embria Health Sciences, www.embriahealth.com, combines science and nature to bring high-quality, research-based natural ingredients to the global human nutrition market. Embria’s flagship ingredient, EpiCor, is an all-natural product designed to modulate and balance the human immune system and is manufactured using a proprietary technology which produ...

Pulmatrix, Inc.

Pulmatrix, Inc., is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases. Pulmatrix’s lead proprietary therapies, called inhaled cationic airway lining modulators (iCALM™), are a novel approach to prevent and treat acute exacerbations an...


More From BioPortfolio on "Type ineffectively activates neonatal dendritic cells limiting respiratory"

Quick Search

Corporate Database Quicklinks